DK1307473T3 - Oprensning af HBV-antigener til anvendelse i vacciner - Google Patents

Oprensning af HBV-antigener til anvendelse i vacciner

Info

Publication number
DK1307473T3
DK1307473T3 DK01960630T DK01960630T DK1307473T3 DK 1307473 T3 DK1307473 T3 DK 1307473T3 DK 01960630 T DK01960630 T DK 01960630T DK 01960630 T DK01960630 T DK 01960630T DK 1307473 T3 DK1307473 T3 DK 1307473T3
Authority
DK
Denmark
Prior art keywords
vaccines
purification
hbv antigens
hbv
antigens
Prior art date
Application number
DK01960630T
Other languages
Danish (da)
English (en)
Inventor
Heyder Koen De
Peter Schu
Michelle Serantoni
Opstel Omer Van
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0019728.5A external-priority patent/GB0019728D0/en
Priority claimed from GB0101334A external-priority patent/GB0101334D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK1307473T3 publication Critical patent/DK1307473T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK01960630T 2000-08-10 2001-08-07 Oprensning af HBV-antigener til anvendelse i vacciner DK1307473T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0019728.5A GB0019728D0 (en) 2000-08-10 2000-08-10 Novel treatment
GB0101334A GB0101334D0 (en) 2001-01-18 2001-01-18 Novel compounds

Publications (1)

Publication Number Publication Date
DK1307473T3 true DK1307473T3 (da) 2006-05-01

Family

ID=26244821

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01960630T DK1307473T3 (da) 2000-08-10 2001-08-07 Oprensning af HBV-antigener til anvendelse i vacciner
DK05077471T DK1666487T3 (da) 2000-08-10 2001-08-07 Oprensning af hbv-antigener til brug i vacciner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05077471T DK1666487T3 (da) 2000-08-10 2001-08-07 Oprensning af hbv-antigener til brug i vacciner

Country Status (35)

Country Link
US (3) US20030235590A1 (cg-RX-API-DMAC7.html)
EP (2) EP1307473B1 (cg-RX-API-DMAC7.html)
JP (2) JP2004505992A (cg-RX-API-DMAC7.html)
KR (1) KR100804922B1 (cg-RX-API-DMAC7.html)
CN (1) CN1468256B (cg-RX-API-DMAC7.html)
AP (1) AP2003002734A0 (cg-RX-API-DMAC7.html)
AR (1) AR030325A1 (cg-RX-API-DMAC7.html)
AT (2) ATE412665T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001282073B2 (cg-RX-API-DMAC7.html)
BG (1) BG66038B1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0113155C1 (cg-RX-API-DMAC7.html)
CA (2) CA2740282A1 (cg-RX-API-DMAC7.html)
CY (2) CY1106310T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303217B6 (cg-RX-API-DMAC7.html)
DE (2) DE60116107T2 (cg-RX-API-DMAC7.html)
DK (2) DK1307473T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ3470A1 (cg-RX-API-DMAC7.html)
EA (1) EA006433B1 (cg-RX-API-DMAC7.html)
EG (1) EG25829A (cg-RX-API-DMAC7.html)
ES (2) ES2314555T3 (cg-RX-API-DMAC7.html)
HU (1) HU228932B1 (cg-RX-API-DMAC7.html)
IL (2) IL154301A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001235A (cg-RX-API-DMAC7.html)
MY (1) MY128999A (cg-RX-API-DMAC7.html)
NO (1) NO20030635L (cg-RX-API-DMAC7.html)
NZ (1) NZ524012A (cg-RX-API-DMAC7.html)
OA (1) OA12361A (cg-RX-API-DMAC7.html)
PE (1) PE20020287A1 (cg-RX-API-DMAC7.html)
PL (1) PL204736B1 (cg-RX-API-DMAC7.html)
PT (1) PT1666487E (cg-RX-API-DMAC7.html)
SI (2) SI1307473T1 (cg-RX-API-DMAC7.html)
SK (2) SK288079B6 (cg-RX-API-DMAC7.html)
UA (1) UA79735C2 (cg-RX-API-DMAC7.html)
UY (1) UY26882A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002012287A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0202901D0 (en) * 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
WO2007008780A2 (en) * 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
JP2009503051A (ja) * 2005-08-02 2009-01-29 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 油含有アジュバントと界面活性剤含有アジュバントとの間の干渉の減少
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0612142D0 (en) 2006-06-20 2006-08-02 Secr Defence Spreading modulation spectrum control
NZ575273A (en) * 2006-09-07 2012-02-24 Glaxosmithkline Biolog Sa Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid
WO2008135514A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
JP5214627B2 (ja) * 2007-10-30 2013-06-19 京セラ株式会社 弾性波装置
US8250102B2 (en) * 2008-03-14 2012-08-21 Microsoft Corporation Remote storage and management of binary object data
KR100959145B1 (ko) 2008-03-21 2010-05-25 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사 입자의 생산 및 정제 방법
CA2826508C (en) * 2008-05-23 2016-07-19 The Regents Of The University Of Michigan Nanoemulsion vaccines
MX2011012623A (es) * 2009-05-27 2011-12-14 Glaxosmithkline Biolog Sa Construcciones de casb7439.
ES2594895T3 (es) * 2011-01-14 2016-12-23 Hal Allergy Holding B.V. Inmunoensayo para la determinación directa de contenido de antígeno en productos que comprenden partículas de antígeno acoplado a un adyuvante
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
CN106222129A (zh) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
JP7404226B2 (ja) 2017-07-18 2023-12-25 セラム インスティテュート オブ インディア プライベート リミティド 向上した安定性、高度の免疫原性、及び減少した反応源性を有する免疫原性組成物、並びにその調製プロセス
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
JP2022524007A (ja) 2019-03-05 2022-04-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｂ型肝炎免疫化レジメンおよび組成物
CN112972671B (zh) * 2019-12-13 2024-04-19 远大赛威信生命科学(南京)有限公司 药物组合物及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1030777A (en) * 1963-12-06 1966-05-25 Ciba Ltd Method of preparing a vaccine against trypanosoma cruzi infections
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4720385A (en) * 1983-03-29 1988-01-19 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
KR850001534A (ko) 1983-08-22 1985-03-30 제임스 에프. 나우톤 형질전환된 효모로 부터 유도된 면역원성 HBsAg
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0304578B1 (en) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide comprising hepatitis B surface antigen
EP0299108B1 (en) 1987-07-17 1994-05-18 Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses
EP0314240A3 (en) * 1987-10-26 1990-03-28 Merck & Co. Inc. Process for purifying recombinant hepatitis antigens
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5242812A (en) * 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
US5274081A (en) * 1989-09-20 1993-12-28 Immuno A.G. Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
AU9052091A (en) 1990-12-20 1992-07-22 Smithkline Beecham Biologicals (Sa) Vaccines based on hepatitis b surface antigen
JP3026029B2 (ja) 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 組換え水痘ウイルスとその作製法
AU657168B2 (en) 1991-09-18 1995-03-02 Amgen, Inc. Hepatitis B vaccine with bile salt adjuvant
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
SK279188B6 (sk) 1992-06-25 1998-07-08 Smithkline Beecham Biologicals S.A. Vakcínová kompozícia spôsob jej prípravy a použiti
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
NZ337543A (en) * 1994-10-24 2002-06-28 Allergan Inc Composition comprising avian antitoxin against clostridial neurotoxin protein and method for producing recombinant antitoxin proteins are provided for
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
KR20010041629A (ko) * 1998-03-09 2001-05-25 장 스테판느 혼합 백신 조성물
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
WO2000037104A1 (en) * 1998-12-23 2000-06-29 Merck & Co., Inc. Improved recombinant hepatitis b surface antigen
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах

Also Published As

Publication number Publication date
KR20030029127A (ko) 2003-04-11
AP2003002734A0 (en) 2003-03-31
SK1692003A3 (en) 2003-08-05
DE60116107D1 (de) 2006-01-26
NZ524012A (en) 2004-02-27
NO20030635L (no) 2003-04-01
UY26882A1 (es) 2002-03-22
UA79735C2 (uk) 2007-07-25
EP1666487B1 (en) 2008-10-29
EA200300129A1 (ru) 2003-10-30
IL154301A0 (en) 2003-09-17
AU2001282073B2 (en) 2005-01-20
ATE412665T1 (de) 2008-11-15
SK288069B6 (sk) 2013-05-03
DE60116107T2 (de) 2006-08-03
BRPI0113155B1 (pt) 2018-11-21
JP2004505992A (ja) 2004-02-26
AR030325A1 (es) 2003-08-20
BR0113155A (pt) 2003-07-08
ES2254464T3 (es) 2006-06-16
PT1666487E (pt) 2008-12-26
KR100804922B1 (ko) 2008-02-20
US8624004B2 (en) 2014-01-07
BRPI0113155B8 (pt) 2019-08-13
CZ303217B6 (cs) 2012-05-30
JP2012255015A (ja) 2012-12-27
HUP0302951A3 (en) 2004-10-28
IL154301A (en) 2009-11-18
SI1666487T1 (sl) 2009-02-28
BG66038B1 (bg) 2010-11-30
EA006433B1 (ru) 2005-12-29
CN1468256B (zh) 2010-10-27
ES2314555T3 (es) 2009-03-16
AU8207301A (en) 2002-02-18
EP1307473B1 (en) 2005-12-21
MY128999A (en) 2007-03-30
JP5559847B2 (ja) 2014-07-23
DK1666487T3 (da) 2009-01-12
WO2002012287A1 (en) 2002-02-14
CA2427475C (en) 2011-07-05
CY1106310T1 (el) 2011-10-12
MXPA03001235A (es) 2004-07-16
PE20020287A1 (es) 2002-06-20
EP1666487A1 (en) 2006-06-07
HU228932B1 (en) 2013-06-28
DE60136400D1 (de) 2008-12-11
PL204736B1 (pl) 2010-02-26
CA2427475A1 (en) 2002-02-11
US20090123496A1 (en) 2009-05-14
EG25829A (en) 2012-09-02
DZ3470A1 (fr) 2002-02-14
BG107545A (bg) 2004-01-30
CZ2003385A3 (cs) 2003-06-18
ATE313558T1 (de) 2006-01-15
CA2740282A1 (en) 2002-02-11
US20030235590A1 (en) 2003-12-25
OA12361A (en) 2004-04-13
US20060159705A1 (en) 2006-07-20
PL362322A1 (en) 2004-10-18
NO20030635D0 (no) 2003-02-07
CN1468256A (zh) 2004-01-14
SI1307473T1 (sl) 2006-04-30
SK288079B6 (sk) 2013-06-03
HK1056884A1 (en) 2004-03-05
CY1108789T1 (el) 2014-04-09
BRPI0113155C1 (pt) 2021-05-25
HUP0302951A2 (hu) 2003-12-29
EP1307473A1 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
DK1307473T3 (da) Oprensning af HBV-antigener til anvendelse i vacciner
NO20026175L (no) Vaksinesammensetning
PL363005A1 (pl) Szczepionki
NO20031483L (no) Vaksine
NO20024172L (no) Vaksine
IS7133A (is) Afleiða beta-amyloid - T-frumu-mótefnavísisbóluefni
DK1524993T3 (da) Neisseria-vaccinesammensætning omfattende en kombination af antigener
DK1023904T3 (da) Adjuvanser til anvendelse i vacciner
DE60114714D1 (de) Silikon-Entschäumer-Zusammensetzung
NO2012018I1 (no) Canakinumab eller direkte ekvivalenter derav
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
HUP0204250A3 (en) Use of hiv-protein or -polynucleotide for vaccine produce
DK1406656T3 (da) Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer
DE60109554D1 (de) Tragender Wegwerfartikel
DK1309545T3 (da) Fremgangsmåde til fremstilling af alkylarylsulfonater
NO20030239L (no) Modifisert virus
DK1326836T3 (da) Fremgangsmåde til fremstilling af 3-amino-2-chlor-4-methylpyridin
IS6381A (is) Nýjung við notkun mótefna í bóluefni
DE60139633D1 (de) Transformierender wachstumsfaktor alpha enthaltende impfstoffzusammensetzung
DK1286940T3 (da) Fremgangsmåde til fluormethylering af alkoholer
DE60112390D1 (de) Verfahren zur Herstellung von Isobuten-Isopren Kopolymeren
DK1180041T3 (da) Vaccine med ISA-virus
DK1282598T3 (da) Fremgangsmåde til fremstilling af sulfonyl-benzoylguanidiniumsalte
DE50106825D1 (de) Gasgargerät zur thermischen gargutzubereitung
DK1232279T3 (da) Fremgangsmåde til fremstilling af optisk aktive aminer